Search Results - "PATIL, NAMRATA S."

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer by Patil, Namrata S., Nabet, Barzin Y., Müller, Sören, Koeppen, Hartmut, Zou, Wei, Giltnane, Jennifer, Au-Yeung, Amelia, Srivats, Shyam, Cheng, Jason H., Takahashi, Chikara, de Almeida, Patricia E., Chitre, Avantika S., Grogan, Jane L., Rangell, Linda, Jayakar, Sangeeta, Peterson, Maureen, Hsia, Allison W., O’Gorman, William E., Ballinger, Marcus, Banchereau, Romain, Shames, David S.

“…Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients, based on their…”
Get full text

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab by Iwai, Toshiki, Sugimoto, Masamichi, Patil, Namrata S., Bower, Daniel, Suzuki, Miho, Kato, Chie, Yorozu, Keigo, Kurasawa, Mitsue, Shames, David S., Kondoh, Osamu

“…Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical…”
Get full text

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma by Patil, Namrata S, Righi, Luisella, Koeppen, Hartmut, Zou, Wei, Izzo, Stefania, Grosso, Federica, Libener, Roberta, Loiacono, Marco, Monica, Valentina, Buttigliero, Consuelo, Novello, Silvia, Hegde, Priti S, Papotti, Mauro, Kowanetz, Marcin, Scagliotti, Giorgio V

“…Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, and relatively chemoresistant and radioresistant malignancy with limited therapeutic…”
Get more information

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients by Patil, Namrata S, Zou, Wei, Mocci, Simonetta, Sandler, Alan, Ballinger, Marcus, Flynn, Susan, Kowanetz, Marcin, Hegde, Priti S

“…Overall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum…”
Get full text

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study by Cho, Byoung Chul, Abreu, Delvys Rodriguez, Hussein, Maen, Cobo, Manuel, Patel, Anjan J, Secen, Nevena, Lee, Ki Hyeong, Massuti, Bartomeu, Hiret, Sandrine, Yang, James Chih Hsin, Barlesi, Fabrice, Lee, Dae Ho, Ares, Luis Paz, Hsieh, Robert W, Patil, Namrata S, Twomey, Patrick, Yang, Xiaoying, Meng, Raymond, Johnson, Melissa L

“…Targeted inhibition of the PD-L1–PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory…”
Get full text

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer by Assaf, Zoe June F., Zou, Wei, Fine, Alexander D., Socinski, Mark A., Young, Amanda, Lipson, Doron, Freidin, Jonathan F., Kennedy, Mark, Polisecki, Eliana, Nishio, Makoto, Fabrizio, David, Oxnard, Geoffrey R., Cummings, Craig, Rode, Anja, Reck, Martin, Patil, Namrata S., Lee, Mark, Shames, David S., Schulze, Katja

“…One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal…”
Get full text

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer by Rudin, Charles M, Liu, Stephen V, Soo, Ross A, Lu, Shun, Hong, Min Hee, Lee, Jong-Seok, Bryl, Maciej, Dumoulin, Daphne W, Rittmeyer, Achim, Chiu, Chao-Hua, Ozyilkan, Ozgur, Johnson, Melissa, Navarro, Alejandro, Novello, Silvia, Ozawa, Yuichi, Tam, Sammi Hiu, Patil, Namrata S, Wen, Xiaohui, Huang, Meilin, Hoang, Tien, Meng, Raymond, Reck, Martin

“…The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of…”
Get full text

Automated tumor immunophenotyping predicts clinical benefit from anti‐PD‐L1 immunotherapy by Li, Xiao, Eastham, Jeffrey, Giltnane, Jennifer M, Zou, Wei, Zijlstra, Andries, Tabatsky, Evgeniy, Banchereau, Romain, Chang, Ching‐Wei, Nabet, Barzin Y, Patil, Namrata S, Molinero, Luciana, Chui, Steve, Harryman, Maureen, Lau, Shari, Rangell, Linda, Waumans, Yannick, Kockx, Mark, Orlova, Darya, Koeppen, Hartmut

“…Cancer immunotherapy has transformed the clinical approach to patients with malignancies, as profound benefits can be seen in a subset of patients. To identify…”
Get full text

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade by Nabet, Barzin Y, Hamidi, Habib, Lee, Myung Chang, Banchereau, Romain, Morris, Stefanie, Adler, Leah, Gayevskiy, Velimir, Elhossiny, Ahmed M, Srivastava, Minu K, Patil, Namrata S, Smith, Kiandra A, Jesudason, Rajiv, Chan, Caleb, Chang, Patrick S, Fernandez, Matthew, Rost, Sandra, McGinnis, Lisa M, Koeppen, Hartmut, Gay, Carl M, Minna, John D, Heymach, John V, Chan, Joseph M, Rudin, Charles M, Byers, Lauren A, Liu, Stephen V, Reck, Martin, Shames, David S

“…Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A…”
Get more information

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., Patil, Namrata S.

“…Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 )…”
Get full text

Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150 by Mang, Anika, Zou, Wei, Rolny, Vinzent, Reck, Martin, Cigoianu, Daniel, Schulze, Katja, Holdenrieder, Stefan, Socinski, Mark A, Shames, David S, Wehnl, Birgit, Patil, Namrata S

“…Patients with non-small cell lung cancer (NSCLC) and stable disease (SD) have an unmet clinical need to help guide early treatment adjustments. To evaluate the…”
Get full text

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., Patil, Namrata S.

Get full text

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., Patil, Namrata S.

Get full text

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells by Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., Patil, Namrata S.

Get full text

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy by Zou, Wei, Yaung, Stephanie J, Fuhlbrück, Frederike, Ballinger, Marcus, Peters, Eric, Palma, John F, Shames, David S, Gandara, David, Jiang, Yuqiu, Patil, Namrata S

“…Identification of predictors for overall survival (OS) allows timely detection of clinical efficacy signals and therefore facilitates treatment decisions. We…”
Get more information

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade by Banchereau, Romain, Chitre, Avantika S., Scherl, Alexis, Wu, Thomas D., Patil, Namrata S., de Almeida, Patricia, Kadel, III, Edward E., Madireddi, Shravan, Au-Yeung, Amelia, Takahashi, Chikara, Chen, Ying-Jiun, Modrusan, Zora, McBride, Jacqueline, Nersesian, Rhea, El-Gabry, Ehab A., Robida, Mark D., Hung, Jeffrey C., Kowanetz, Marcin, Zou, Wei, McCleland, Mark, Caplazi, Patrick, Eshgi, Shadi Toghi, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Mathews, W. Rodney, Powles, Thomas, Mariathasan, Sanjeev, Grogan, Jane, O'Gorman, William E

“…BackgroundCD8+ tissue-resident memory T (TRM) cells, marked by CD103 (ITGAE) expression, are thought to actively suppress cancer progression, leading to the…”
Get full text

Relationship between kinetic stability and immunogenicity of HLA‐DR4/peptide complexes by Hall, Frances C., Rabinowitz, Joshua D., Busch, Robert, Visconti, Kevin C., Belmares, Michael, Patil, Namrata S., Cope, Andrew P., Patel, Salil, McConnell, Harden M., Mellins, Elizabeth D., Sonderstrup, Grete

“…Immunodominant T cell epitopes from the autoantigen human cartilage glycoprotein 39 have previously been mapped in the context of HLA‐DR*0401 and *0402, using…”
Get full text

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial by Kim, Tae Won, Bedard, Philippe L, LoRusso, Patricia, Gordon, Michael S, Bendell, Johanna, Oh, Do-Youn, Ahn, Myung-Ju, Garralda, Elena, D'Angelo, Sandra P, Desai, Jayesh, Hodi, F Stephen, Wainberg, Zev, Delord, Jean-Pierre, Cassier, Phillippe A, Cervantes, Andrés, Gil-Martin, Marta, Wu, Benjamin, Patil, Namrata S, Jin, Yanling, Hoang, Tien, Mendus, Diana, Wen, Xiaohui, Meng, Raymond, Cho, Byoung Chul

“…Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab…”
Get more information

579-B TIGIT and PD-L1 co-blockade promotes clonal expansion of non-exhausted anti-tumour CD8+ T cells by facilitating costimulation by Nutsch, Katherine, Banta, Karl L, Wu, Thomas D, Tran, Charles W, Mittman, Stephanie, Duong, Ellen, Nabet, Barzin Y, Qu, Yan, Patil, Namrata S, Chiang, Eugene Y, Mellman, Ira

“…BackgroundBlockade of the immune checkpoints PD-1 and TIGIT has demonstrated activity in mouse tumour models and human cancer patients. Although these…”
Get full text

DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms by Rinderknecht, Cornelia H, Roh, Sujin, Pashine, Achal, Belmares, Michael P, Patil, Namrata S, Lu, Ning, Truong, Phi, Hou, Tieying, Macaubas, Claudia, Yoon, Taejin, Wang, Nan, Busch, Robert, Mellins, Elizabeth D

“…DM catalyses class II-associated invariant chain peptide (CLIP) release, edits the repertoire of peptides bound to major histocompatibility complex (MHC) class…”
Get full text